Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,013 public trials 2,032 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program

NCT02582320

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • U.O.C. Ematologia e Terapia Cellulare - Ospedale "C. e G. Mazzoni" di Ascoli Piceno Ascoli Piceno, Italy
  • U.O.C di Ematologia P.O. "S.Giuseppe Moscati" - 2° piano Aversa, Italy
  • UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro Bari, Italy
  • Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi Bologna, Italy
View all 47 locations
View Trial Details
Completed

A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma

NCT02495922

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Studienzentrum Aschaffenburg Aschaffenburg, Germany
  • MVZ Onkologie gGmbH der Klinikum Mittelbaden gGmbH Baden-Baden, Germany
  • HELIOS Klinikum, Klinik für Hämatologie, Onkologie und Immunologie Berlin, Germany
  • Onkologisches MVZ Berlin Tegel Berlin, Germany
View all 68 locations
View Trial Details
Completed

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

NCT03525834

Conditions
Angiomyolipoma, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +26 more
Locations
  • Novartis Investigative Site Wuhan, Hubei, China
  • Novartis Investigative Site Shanghai, Shanghai Municipality, China
  • Novartis Investigative Site Chengdu, Sichuan, China
  • Novartis Investigative Site Beijing, China
View Trial Details
Completed

A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma

NCT01965353

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Brigham and Women's Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Duke University Medical Center Durham, North Carolina, United States
View Trial Details
Completed

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

NCT01723020

Conditions
Advanced Malignancy, Advanced Solid Tumors, Astrocytoma, +26 more
Locations
  • Research Site Santa Monica, California, United States
  • Research Site Norwalk, Connecticut, United States
  • Research Site Boston, Massachusetts, United States
  • Research Site Boston, Massachusetts, United States
View all 14 locations
View Trial Details

Related conditions